H.C. Wainwright analyst Matthew Caufield downgraded Aldeyra to Neutral from Buy with a price target of $2, down from $10, after the company received a complete response letter from the FDA related to reproxalap for the topical treatment of the signs and symptoms of dry eye disease. The firm reduced its probability of success for reproxalap from 75% to 40% and downgraded Aldeyra.
